Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 8/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24140931 | 0.83 | BACE1 (0.55) | KDRBACE1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL25877652 | 0.78 | NAMPT (0.52) | NPC1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL25877550 | 0.77 | L3MBTL1 (0.48) | NPC1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL25877751 | 0.77 | MAPT (0.47) | SMN1; SMN2LMNAMAPTMEN1KMT2A | |
| SCHEMBL25877680 | 0.76 | SIRT2 (0.46) | NPC1RAB9ALMNAMAPTMEN1 | |
| SCHEMBL1455190 | 0.76 | LMNA (0.62) | KDRAURKBSMN1; SMN2GRM4LMNA | |
| SCHEMBL29217379 | 0.74 | MEN1 (0.62) | KDRAURKBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL25877683 | 0.72 | HTT (0.53) | RAB9ASMN1; SMN2LMNAMAPTMEN1 | |
| SCHEMBL16592576 | 0.72 | KDR (0.81) | KDRAURKBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL25877386 | 0.72 | MAPK1 (0.47) | NPC1RAB9ASMN1; SMN2PKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| WO-2021263079-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | FEN1, ERCC4, DCLRE1B | KDR 4192/4885AURKB 3421/4885BACE1 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.